Bluebird Ventures

Bluebird Ventures investment thesis

Epirium Bio Mitochondrial Biogenesis Epirium Bio is developing a new class of therapeutics that stimulates muscle growth and strength as well as benefiting biogenesis in other tissues. The Company has clinical data in several degenerative muscle disease indications including Becker’s Muscular Dystrophy. Founded by George Schreiner MD PhD and Sundeep Dugar PhD. Series A Investor and Board member Forty Seven Immuno-Oncology Forty Seven developed an antibody against CD47, a “Don’t Eat Me” signal that regulates immune activity against many cancers. Founded by Irv Weissman MD (Director of the Stanford Stem Cell Institute) and Ravi Majeti MD PhD, Chair of Hematology at Stanford. The Company went public in 2018 and was acquired by Gilead in 2019 for $4.9 billion. Series A Investor and Lead Direct

Bluebird Ventures team (1)

Partners and principals at Bluebird Ventures:

• Jeffrey Bird — sweet spot $1.5M

Bluebird Ventures portfolio companies

Companies listed on Bluebird Ventures's public materials include: ABOUT, PORTFOLIO, NEWS, Epirium Bio, Forty Seven, Kriya Therapeutics, Medikine Therapeutics, Nutcracker Therapeutics, Procyrion, About, Portfolio, News.

Is Bluebird Ventures a fit for your round?

Upload your pitch deck and see whether anyone at Bluebird Ventures appears in your top matches.